Erbitux clears late-stage hurdle for lung cancer

ImClone once again is feeling the tonic effects of positive trial data. Its stock price took off this morning, rising 19 percent after its European partner, Merck KGaA, reported that Erbitux helped increase the survival rate of lung cancer patients. The data may help clear the way to a new approval with blockbuster potential. The trial volunteers were diagnosed with advanced non-small cell lung cancer and divided into two groups that received either a combination of Erbitux and chemotherapy or chemotherapy alone. Last July Erbitux failed a separate late-stage study as a treatment for lung cancer.

Good news for ImClone and its U.S. partner, Bristol-Myers, was bad news for Genentech, which saw its share price clip on the news of a potential competitor.

 

- see ImClone's release on the trial
- read the AP report

ALSO: Repligen says that ImClone has agreed to pay $65 million to settle patent infringement charges related to Erbitux. Release

Related Articles:
ImClone names new CEO. Report
ImClone shares dive after Erbitux fails a Phase III. Report
Erbitux data underscores leaked disappointment. Report
ImClone buoyed by new Erbitux data. Report
ImClone touts survival rate in Erbitux cancer trial. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.